Zhou, T. (2026). A phase 2 study of vilanterol in combination with a CLDN18.2 bispecific antibody in patients with advanced CLDN18.2-positive pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.2_suppl.748